Cabozantinib (cabozantinib) effects and efficacy

Cabozantinib is a multi-receptor tyrosine kinase inhibitor used for the treatment of progressive metastatic medullary thyroid carcinoma. Used for patients who are ineffective or unqualified for radioactive iodine(iodine-131)12 Treatment of locally advanced or metastatic differentiated thyroid cancer (DTC) that has progressed after VEGFR-targeted therapy in adults and pediatric patients > 10 years of age and older. A single agent for the treatment of patients with advanced renal cell carcinoma(RCC). For the treatment of patients with hepatocellular carcinoma (HCC) previously treated with sorafenib.

potentCYP3A4Inhibitors:Possible pharmacokinetic interactions (Increased systemic exposure of cabozantinib). If alternative treatments are available, avoid concomitant use. If concomitant therapy cannot be avoided, reduce the daily dose of cabozantinib capsules by 40 mg (for example, from 140 mg daily to 100 mg daily or from 100 mg daily) mgto 60 mg daily)and the daily dose of cabozantinib tablets reduced by 20 mg (For example, for pediatric patients with BSA <1.2 m, daily 60 mg to 40 mg, or daily 40 mg to 20 mg, or daily 20 mg to every other day 20 mg2). If a strong CYP3A4 inhibitor is discontinued, proceed to the same dosage as before starting the strong CYP3A4 inhibitor Dosage recoveryAfter treatment with cabozantinib(Discontinuation ofCYP3A4 inhibitor2-3days).

PotentialCYP3A4Inducers:Possible pharmacokinetic interactions with long-term coadministration (Reduce systemic exposure of cabozantinib). If alternative treatments are available, avoid long-term concomitant use. If concomitant therapy cannot be avoided, increase the daily dose of cabozantinib capsules by 40 mg (for example, 140 mg daily to 180 mg daily or 100 mg daily). mgto140 mg ),and a daily dose of cabotinib20mg(such as daily 60mg to 80 mg or 40 mg to 60 mg per day. If the active CYP3A4 inducer is discontinued, resume cabotinib treatment(After discontinuing CYP3A4 inducer 2-3days). Do not exceed a daily dose of cabozantinib capsules of 180 mg. Do not exceed the daily dosage of cabozantinib 80 mg from one tablet. Laos ASEAN Pharmaceuticals, United Pharmaceuticals, Lucius Pharmaceuticals, Element Pharmaceuticals, etc. are produced, and the cost per box is less than 20mg*90 capsules1,000 yuan. The retail price of Everest Pharmaceuticals, Yaopin International and Beacon Pharmaceuticals in Bangladesh is around 20mg*90 capsules 2000 per box. If you want to get more high-quality information, you can contact YaDE. YaDE will do its best to learn more about high-quality overseas drugs for you.